4 news items
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
PCSA
28 Mar 24
discontinuation, more significant cancer response, and a greater number of patients -- over 250,000 patients treated each year for each drug -- who will benefit
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
PCSA
25 Mar 24
NGCs are expected to include fewer patients experiencing side effects that lead to dose discontinuation, more significant cancer response
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
PCSA
21 Feb 24
side effects that lead to dose discontinuation, more significant cancer response, and a greater number of patients -- over 250,000 patients treated each
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
PCSA
14 Feb 24
, more significant cancer response, and a greater number of patients -- over 250,000 patients treated each year for each drug -- who will benefit from
- Prev
- 1
- Next